Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
about
Rituximab for rheumatoid arthritisAbatacept for rheumatoid arthritisIL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in miceMucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapyNew insights into the impact of neuro-inflammation in rheumatoid arthritisUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Rituximab for Rheumatoid Arthritis.Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsThe safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesComparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges.Post-stroke infection: a role for IL-1ra?Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.Rationale of using different biological therapies in rheumatoid arthritis.Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion.Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.Treatment of Sarcoidosis.The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.Identification of cytomegalovirus and human herpesvirus-6 DNA in a patient with corneal endotheliitis.Nocardiosis in a patient with rheumatoid arthritis treated with rituximab and a summary of reported cases.Abatacept treatment for rheumatoid arthritisImmune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease.A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.An update on the pathology and clinical management of gouty arthritis.IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice.Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells.The efficacy and safety of abatacept in rheumatoid arthritis.Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisRituximab in idiopathic membranous nephropathy.Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice.Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis.The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
P2860
Q24186568-30FEDD15-8DAB-443D-9881-41C070A47647Q24240131-A4398E9B-A9D7-4A2F-8CE9-2CC7E3F53880Q27008536-FBF62D3E-8558-48CF-AD3D-D46D9AF11B39Q27010562-E083E116-FBCD-4D34-BC80-73DC32FE006DQ27023946-5F4B4905-B8B1-48F4-B934-422971CC7EE7Q27691388-4F6F27FA-50DE-4A16-A997-8ED057CCF8DEQ28080246-1A66A18A-A5CE-41B6-A3F9-9E1C93DD4D0FQ28084309-B08A9CF9-2417-463F-8FBC-848193499A0FQ30397234-DB156E13-3AD3-417F-A10F-A31A6CA86206Q30811550-C1038724-9561-4AAD-93E5-25649109279AQ31153194-C95D727B-235C-4AAD-AEEB-4C32A71404C2Q33385389-3DAC6953-CE9B-4FD5-A5DF-1D67AFADAA8AQ33573112-393A8076-3E26-4349-9BB8-F8399B95E8BAQ33578361-87E69B27-C5DA-49A0-BC55-FFD8A74290E3Q33778719-4AEEDE7B-5E5D-4D49-B6C6-730875D0368FQ33785735-EE1B2302-58E4-49DB-B417-AB070E058F7DQ33897235-6B21990D-ECD9-4DD0-83ED-7DBE3511B5C0Q33923452-161E4650-008A-4E45-B8E3-59967DF9DE19Q34065002-FE90892D-5B95-4814-B976-A0C093DA5B51Q34153073-1B8CFD11-FDAB-4B67-8884-9F31A3FA53B7Q34404386-2CE1F53E-985B-4462-A064-333446D3B653Q34420356-7DCD7407-4A7A-4EEF-A463-D977B508BFFEQ34431953-CD13DB33-83A4-4B0E-9CD0-83A0AD83654DQ34477003-6FE8A72B-295E-4A60-9CF3-8157A28780F5Q34486116-5E8724C8-5EA0-4CD5-BB4A-A7ABEAD00E44Q34514777-0CDE417B-C5A2-45E3-A56C-3814D2AB210DQ34535119-0AD14C1E-3B80-4F3F-9593-0ADD27FF1E19Q34588972-84621FDC-0B32-4481-92B0-023FD49AE746Q34611614-A350993E-ADFB-4721-BDCB-D6C4E947F413Q34758768-A933B3C7-5437-4EB2-AED6-10F9FBF4BF51Q35237588-E7AA8E9B-2D62-4CFD-B05E-65E721B8E978Q35643985-23425418-1316-4718-B4C3-59B5944A21C9Q35681138-D9E4F1A6-0671-4CB9-A726-181830DF36EBQ35980026-3B606100-0D86-4794-B934-D23681B1A49DQ36059373-C95FC52C-4220-4985-A6C0-034F823EC684Q36086443-2A0AC707-F62D-4495-8646-175EDF27EF5BQ36109197-B3D71B2B-601B-4500-AFDD-017B0B0BCCB4Q36298389-51ED8E86-FE68-47D2-A5A7-EF15BB34224AQ36633284-B4FA5198-E57C-4B56-B399-9129D3949917Q36761926-59DB16D4-2EFC-42C4-A062-EBBDAC875DA7
P2860
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Risk of serious infections dur ...... sed placebo-controlled trials.
@ast
Risk of serious infections dur ...... sed placebo-controlled trials.
@en
Risk of serious infections dur ...... sed placebo-controlled trials.
@nl
type
label
Risk of serious infections dur ...... sed placebo-controlled trials.
@ast
Risk of serious infections dur ...... sed placebo-controlled trials.
@en
Risk of serious infections dur ...... sed placebo-controlled trials.
@nl
prefLabel
Risk of serious infections dur ...... sed placebo-controlled trials.
@ast
Risk of serious infections dur ...... sed placebo-controlled trials.
@en
Risk of serious infections dur ...... sed placebo-controlled trials.
@nl
P2093
P2860
P31
P921
P356
P1476
Risk of serious infections dur ...... sed placebo-controlled trials.
@en
P2093
P2860
P356
10.1136/ARD.2007.083188
P407
P5008
P577
2008-01-18T00:00:00Z
2009-01-01T00:00:00Z